MedTrace Logo

Utility of the Administration of Chesnut and Quebracho Extract for Irritable Bowel Syndrome Diarrhea Predominant

NCT05207618 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2022-07-06

No results posted yet for this study

Summary

Irritable bowel syndrome is a highly prevalent disorder and consumes many health resources. Its physiopathogenesis is multifactorial. Some of the factors involved have to do with the alteration of the intestinal microbiota, low-grade inflammation and the alteration of intestinal permeability. Specific tannins have been shown to have prebiotic effects and could be useful in treating this condition. This is an exploratory before-after study that aims to evaluate the effect of a chestnut and quebracho extract on the symptoms of IBS diarrhea predominant, serum cytokine levels, microbiota and intestinal permeability, as well as on metabolomics.

Conditions

Interventions

DIETARY_SUPPLEMENT

ARBOX (QUEBRACHO AND CHESNUT EXTRACT)

ARBOX TWICE A DAY FOR 60 days

Sponsors & Collaborators

  • SILVATEAM

    collaborator UNKNOWN

  • Hospital de Clinicas José de San Martín

    lead OTHER

Principal Investigators

  • MARIA MARTA PISKORZ · NEUROGASTROENTEROLOGIA HOSPITAL DE CLINICAS

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-09-21
Primary Completion
2022-02-20
Completion
2022-04-20

Countries

  • Argentina

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05207618 on ClinicalTrials.gov